<DOC>
	<DOCNO>NCT00217412</DOCNO>
	<brief_summary>This phase I trial study side effect best dose vorinostat give together isotretinoin treat young patient recurrent refractory solid tumor , lymphoma , leukemia . Drugs use chemotherapy , vorinostat , work different way stop growth cancer cell , either kill cell stop dividing . Vorinostat may also stop growth cancer cell block enzymes need cell growth block blood flow cancer . Isotretinoin may cause cancer cell look like normal cell , grow spread slowly . Giving vorinostat together isotretinoin may effective treatment cancer .</brief_summary>
	<brief_title>Vorinostat With Without Isotretinoin Treating Young Patients With Recurrent Refractory Solid Tumors , Lymphoma , Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) vorinostat ( SAHA ) young patient recurrent refractory solid tumor lymphomas . II . Determine MTD SAHA administer combination isotretinoin young patient recurrent refractory neuroblastoma , medulloblastoma/CNS primitive neuroectodermal tumor , atypical teratoid rhabdoid tumor . III . Determine tolerability solid tumor MTD SAHA young patient recurrent refractory leukemia . IV . Determine toxic effect SAHA administer without isotretinoin patient . V. Determine pharmacokinetics drug patient . SECONDARY OBJECTIVES : I . Determine , preliminarily , antitumor activity SAHA administer without isotretinoin patient . II . Correlate pharmacokinetics drug genetic polymorphism ( e.g. , UGT1A1 ) patient . OUTLINE : This multicenter , dose-escalation study vorinostat ( SAHA ) . Group 1 ( solid tumor lymphoma patient ) : Patients receive oral SAHA daily day 1-28 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity.Cohorts 3-6 patient receive escalate dos SAHA maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . An additional 6 patient may treat MTD . Group 2 ( leukemia patient ) : Patients receive SAHA group 1 MTD . Group 3 ( select solid tumor patient ) : Patients receive oral isotretinoin twice daily day 1-14 . Patients also receive SAHA daily day 1-28 OR day 1 , 3 , 5 , 8 , 10 , 12 , 15 , 17 , 19 , 22 , 24 , 26 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity.The MTD SAHA determine group 1 . An additional 6 patient may treat MTD . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Rhabdoid Tumor</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Histologically confirmed* diagnosis 1 following : Recurrent refractory solid tumor lymphoma ( patient group 1 ) Measurable evaluable disease Recurrent refractory leukemia ( patient group 2 ) Greater 25 % blast bone marrow ( i.e. , M3 bone marrow ) Active extramedullary disease allow except leptomeningeal disease Recurrent refractory CNS tumor 1 follow type ( patient group 3 ) : Neuroblastoma Medulloblastoma/CNS primitive neuroectodermal tumor Atypical teratoid rhabdoid tumor No known curative therapy therapy proven prolong survival acceptable quality life exist No bone marrow involvement disease ( patient group 1 3 ) No active CNS leukemia Performance status Lansky 50100 % ( patient ≤ 10 year age ) Performance status Karnofsky 60100 % ( patient &gt; 10 year age ) Absolute neutrophil count ≥ 1,000/mm^3 ( solid tumor patient ) Platelet count ≥ 100,000/mm^3* ( solid tumor patient ) ( 20,000/mm^3** leukemia patient ) Hemoglobin ≥ 8.0 g/dL ( RBC transfusion allow ) ( solid tumor leukemia patient ) Triglycerides &lt; 300 mg/dL ( patient group 3 ) Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT ≤ 5 time ULN Albumin ≥ 2 g/dL Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min Creatinine base age follow : No great 0.8 mg/dL ( patient ≤ 5 year age ) No great 1.0 mg/dL ( patient 6 10 year age ) No great 1.2 mg/dL ( patient 11 15 year age ) No great 1.5 mg/dL ( patient 15 year age ) Negative dipstick protein OR &lt; 1,000 mg protein/24 hour urine collection ( patient group 3 ) No evidence gross hematuria ( patient group 3 ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Body surface area ≥ 0.5 m^2 Neurologic deficits patient CNS tumor must stable ≥ 1 week study entry Able swallow whole capsule No uncontrolled infection Skin toxicity &lt; grade 1 ( patient group 3 ) Recovered prior immunotherapy At least 7 day since prior hematopoietic growth factor At least 7 day since prior antineoplastic biologic agent At least 2 month since prior stem cell transplantation rescue No evidence active graftversushost disease No concurrent biologic therapy immunotherapy More 3 week since prior myelosuppressive chemotherapy ( 6 week nitrosoureas ) recover No concurrent chemotherapy Patients CNS tumor must stable decrease dose dexamethasone ≥ 7 day prior study entry No concurrent dexamethasone antinausea antiemetic therapy Recovered prior radiotherapy At least 2 week since prior local , palliative , smallport radiotherapy At least 3 month since prior totalbody irradiation , radiotherapy craniospinal area , radiotherapy ≥ 50 % pelvis At least 6 week since prior substantial radiotherapy bone marrow No concurrent radiotherapy At least 2 week since prior valproic acid No concurrent investigational agent No concurrent anticancer therapy No concurrent enzymeinducing anticonvulsant</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>